Track Repro Med Systems, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Repro Med Systems, Inc. KRMD · Stock Open Repro Med Systems, Inc. in new tab

3.70 USD
EPS
-0.04
P/B
7.56
ROE
-4.59
Beta
0.52
Target Price
6.13 USD
Repro Med Systems, Inc. logo

Repro Med Systems, Inc.

🧾 Earnings Recap – Q1 2026

KORU Medical Systems’ Q1 revenue growth and international expansion drove a 4.7% stock gain, with top-line results and strategic execution outperforming expectations despite modest near-term contributions from new assets.

  • Revenue rose 22% year-over-year to $11.8 million, reflecting strength in recurring patient volumes and new patient diagnosis starts.
  • Domestic core business grew 12%, fueled by legacy account retention and competitive conversions, maintaining momentum in the SCIg market.
  • International revenue surged 35%, supported by prefilled syringe conversions in Europe and new market distributor orders.
  • Progress continued on non-Ig pipeline assets with Phase III trial advancements and submission of a 510(k) for the Freedom Infusion System with deferoxamine.
  • Management reiterated full-year guidance across revenue, margins, adjusted EBITDA, and cash flow, underscoring confidence in strategic priorities and sustainable profitability.
📅
Loading chart...
Key Metrics
Earnings dateMarch 11, 2027
EPS-0.04
Book Value0.42
Price to Book7.56
Debt/Equity18.04
% Insiders8.214%
Growth
Revenue Growth0.11%
Estimates
Forward P/E90.29
Forward EPS0.04
Target Mean Price6.13

DCF valuation

Model fair value for Repro Med Systems, Inc. (KRMD)
Result
Sign in to run the valuation for KRMD.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus None · mean target 6.13 USD (low 4.50, high 8.00) · as of 11 Nov 2026
Low 4.50
Mean 6.13
High 8.00
Price 3.70
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Repro Med Systems, Inc. Logo Repro Med Systems, Inc. Analysis (KRMD)

United States Health Care Official Website Stock

Is Repro Med Systems, Inc. a good investment? Repro Med Systems, Inc. (KRMD) is currently trading at 3.70 USD. Market analysts have a consensus price target of 6.13 USD. This suggests a potential upside from current levels.

Earnings Schedule: Repro Med Systems, Inc. is expected to release its next earnings report on March 11, 2027. The market consensus estimate for Forward EPS is 0.04.

Investor FAQ

Does Repro Med Systems, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Repro Med Systems, Inc.?

Repro Med Systems, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 11, 2027. The company currently has a trailing EPS of -0.04.

Company Profile

KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.

Exchange Ticker
NMS (United States) KRMD
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion